

**FORM 51-102F3
MATERIAL CHANGE REPORT**

Item 1: Name and Address of Reporting Issuer

Cannvas MedTech Inc. (the “Company” or “Cannvas”)
804-750 West Pender Street
Vancouver, BC V6C 2T7

Item 2: Date of Material Change

July 24 and 26, 2019.

Item 3: News Release

News releases were disseminated on July 24 and 26, 2019 and filed on SEDAR (www.sedar.com).

Item 4: Summary of Material Changes

The Company announced that it has closed the second and final tranches of its non-brokered private placement (the “Private Placement”).

Item 5: Full Description of Material Change

The Company announced that, further to its news release of July 10, 2019, it has closed the second tranche of its Private Placement issuing an additional 2,530,000 units at \$0.20 per unit for aggregate additional gross proceeds of \$506,000 raised. The final tranche of the private placement is expected to close in short order.

The Company paid finder’s fees of \$8,450 and 42,250 finder’s warrants to Mackie Research Capital Corporation on the second tranche of the Private Placement.

The Company announced that, further to its news releases of July 10, 2019 and July 24, 2019, it has closed the final tranche of its Private Placement issuing an aggregate of 2,975,000 units for additional gross proceeds of \$595,000. Due to increased demand, the Private Placement has been oversubscribed by \$102,500, for total gross proceeds of \$2,102,500 raised through the issuance of 10,512,500 units at \$0.20 per unit.

Each unit is comprised of one common share and one transferable common share purchase warrant, with each warrant exercisable into one additional common share at a price of \$0.30 for a period of 2 years. All securities issued are subject to a four-month hold period.

The Company intends to use the proceeds of the Private Placement for developing the technology platforms and general working capital.

About Cannvas MedTech Inc.

Cannvas is a leading digital cannabis education and analytics company delivering accessible and evidence-based education while harnessing the power of data to paint a clearer picture of cannabis consumption across Canada.

Item 6: Reliance on subsection 7.1(2) or (3) of National Instrument 51-102

Not applicable.

Item 7: Omitted Information

None.

Item 8: Executive Officer

For further information, please contact:

CannvasMedTech.com
Contact: ir@cannvasmedtech.com

Item 9: Date of Report

July 26, 2019.